Quick Answer
SAB Biotherapeutics, Inc. reported R&D Expense of $34.35 million for fiscal year 2025.
SAB Biotherapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $34.35M | +13.6% |
| 2024 | $30.25M | +83.2% |
| 2023 | $16.52M | -54.7% |
| 2022 | $36.44M | -36.3% |
| 2021 | $57.18M | +104.9% |
| 2020 | $27.91M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $8.97M | +14.5% | +28.2% |
| June 30, 2025 | $7.00M | +2.6% | -8.6% |
| March 31, 2025 | $7.66M | -6.0% | -2.2% |
| September 30, 2024 | $7.83M | +94.8% | +14.8% |
| June 30, 2024 | $6.82M | +86.3% | -16.3% |
| March 31, 2024 | $8.15M | +79.6% | +102.7% |
| September 30, 2023 | $4.02M | -45.3% | +9.8% |
| June 30, 2023 | $3.66M | -57.3% | -19.3% |
- SAB Biotherapeutics, Inc. showed an increase of +13.6% in R&D Expense compared to the prior fiscal year.
- Over the 2020–2025 period, SAB Biotherapeutics, Inc.’s r&d expense has grown by 23.1% (from $27.91 million to $34.35 million).
- The most recent figure is from SAB Biotherapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 9, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: